GlassScriptPhysician profile
Samantha Carter
NPI 1073520839
$7,295.01
in general payments reported to CMS, 2019-2025
31 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $485 · 2021: $496 · 2022: $1,009 · 2023: $1,332 · 2024: $1,567 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,215 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,215.30 |
| Education | $296.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,479.39 | 2019-2025 | Tremfya, Simponi, Remicade |
| Abbvie INC. | $1,067.88 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $673.89 | 2019-2025 | Dupixent |
| Amgen INC. | $582.90 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $444.67 | 2023-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $370.35 | 2023-2024 | Sotyktu |
| Incyte Corporation | $328.39 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $318.01 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $260.68 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $250.94 | 2019-2025 | |
| Dermavant Sciences, INC. | $237.25 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $201.43 | 2024-2025 | Zoryve |
| Pfizer INC. | $133.48 | 2019-2023 | |
| Genzyme Corporation | $127.61 | 2020-2025 | |
| Galderma Laboratories, L.P. | $121.57 | 2023-2025 | Nemluvio, Aklief, Oracea |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $109.82 | 2019-2020 | |
| Almirall LLC | $106.61 | 2019-2022 | |
| Celgene Corporation | $71.09 | 2019 | |
| Genentech USA, INC. | $70.01 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $64.63 | 2019-2020 | |
| Organon LLC | $47.52 | 2025 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $45.87 | 2020-2025 | Clindacin Etz, Genadur, Neo-Synalar |
| Botanix Sb INC | $35.68 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.63 | 2025 | Spevigo |
| Horizon Therapeutics Plc | $23.28 | 2019 | |
| Mayne Pharma Commercial LLC | $20.83 | 2019 | |
| Fidia Pharma USA INC. | $20.16 | 2025 | |
| Dermira, INC. | $15.26 | 2019 | |
| Verrica Pharmaceuticals INC. | $14.22 | 2024 | Ycanth |
| Mission Pharmacal Company | $13.84 | 2021 | |
| Aclaris Therapeutics, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.